ArticlePediatric rheumatology online journal2025
Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in systemic medication in children and adolescents with JIA: why, when and which patterns.Rheumatology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent development of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have expanded the possibilities of pharmacological treatment for patients with juvenile idiopathic arthritis (JIA). The objective of this study is to evaluate trends in initial prescriptions for these targeted therapies in patients aged 0-18 years with non-systemic JIA in clinical practice. We also identified the approval dates and key regulatory changes for each medication.
methodsA retrospective cohort study was conducted using prescription records from the Wilhelmina Children's Hospital, the largest pediatric rheumatology center in the Netherlands, analyzing data from January 2012 to December 2023. The market introduction of targeted therapies for JIA were extracted from the European Medicines Agency (EMA) database.
resultsOver an 11-year period, first prescriptions dates of 11 bDMARDs and tsDMARDs (N = 672) and 3 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (N = 720) were analysed among 696 patients. TNF-alpha inhibitors accounted for the largest proportion of bDMARDs and tsDMARDs, comprising 79.3%. The prescription of bDMARDs and tsDMARDs increased, from a relative proportion of 32.2% in 2012 to 62.7% in 2023, while the prescription of csDMARDs declined from 67.8% in 2012 to 34.3% in 2023. The prescription of JAK inhibitors rose from 1.6% in 2020 to 5.9% in 2023.
conclusionsThis study provides a comprehensive overview of the implementation of targeted therapies (bDMARDs and tsDMARDs) in non-systemic JIA over the past decade, showing a rise in targeted therapies alongside a decrease in csDMARD prescriptions. While TNF-alpha inhibitors remain the most commonly prescribed, there has been a significant rise in the prescription of JAK inhibitors and other new therapies. Factors such as route of administration, patient comfort, costs and treatment efficacy may influence the adoption of these DMARDs. The findings highlight the need for continued research to identify factors for successful implementation of these therapies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.